Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?

被引：6
|
作者：
Ferrara, Napoleone [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr,Mail Code 0819, La Jolla, CA 92093 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2017年 / 109卷 / 11期
关键词：
ENDOTHELIAL GROWTH-FACTOR; METASTATIC COLORECTAL-CANCER; MONOCLONAL-ANTIBODY; TUMOR VASCULATURE; THERAPY; ANGIOGENESIS; CHEMOTHERAPY; TRIAL; COMBINATION; INHIBITION;
D O I：
10.1093/jnci/djx067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predictive biomarkers for bevacizumab in the first line treatment of ovarian cancer
    Jayson, Gordon
    [J]. ANGIOGENESIS, 2014, 17 (03) : 727 - 727
  • [2] Skin capillary density in ovarian cancer; a potential biomarker of Bevacizumab treatment
    Cass, G.
    Newton, C.
    Pawade, J.
    Kanavou, S.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 : 68 - 68
  • [3] Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer
    Barnett, I.
    Alvarez-Secord, A.
    Cohn, D.
    Leath, C.
    Peterson, B.
    Myers, E.
    Havrilesky, L.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 : S66 - S66
  • [4] Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
    Bais, Carlos
    Mueller, Barbara
    Brady, Mark F.
    Mannel, Robert S.
    Burger, Robert A.
    Wei, Wei
    Marien, Koen M.
    Kockx, Mark M.
    Husain, Amreen
    Birrer, Michael J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11)
  • [5] Bevacizumab adds survival benefit in colorectal cancer
    Susman, E
    [J]. LANCET ONCOLOGY, 2005, 6 (03): : 136 - 136
  • [6] No Benefit to Adding Atezolizumab to Chemo/ Bevacizumab for Ovarian Cancer
    不详
    [J]. ONCOLOGY-NEW YORK, 2024, 38 (07):
  • [7] Progranulin is a good predictive biomarker in ovarian cancer patients followed in first remission
    Han, Jasmine J.
    Yu, Minshu
    Hays, John L.
    Kohn, Elise C.
    [J]. CANCER RESEARCH, 2010, 70
  • [8] MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
    Hutchcraft, Megan L.
    Gallion, Holly H.
    Kolesar, Jill M.
    [J]. DIAGNOSTICS, 2021, 11 (01)
  • [9] A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer
    Lee, Chee
    Gebski, Val
    Francis, Katherine
    Grenier, Julien
    Welz, Julia
    Mosconi, Anna Maria
    Rubio-Perez, Maria Jesus
    Grimm, Christoph
    Matsumoto, Takashi
    Vergote, Ignace
    Colombo, Nicoletta
    Mirza, Mansoor Raza
    Follana, Philippe
    de Gregorio, Nikolaus
    Zamagni, Claudio
    Garcia-Garcia, Yolanda
    Meunier, Jerome
    Pujade-Lauraine, Eric
    Friedlander, Michael
    Ray-Coquard, Isabelle
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S160 - S160
  • [10] SKIN CAPILLARY DENSITY AS A NOVEL BIOMARKER OF CYTOTOXIC AND BEVACIZUMAB TREATMENT IN OVARIAN CANCER: A PROSPECTIVE CLINICAL TRIAL
    Cass, G.
    Lewes, R.
    Pawade, J.
    Newton, C.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A209 - A210
12345